PD L1 News and Research

RSS

Global study shows long-term survival benefit for a subset of patients with advanced lung cancer

According to the results of a large, global study led by Yale Cancer Center researchers, even a tiny amount of a biomarker known as PD-L1 (programmed death-ligand1) can predict a long-term survival benefit from using pembrolizumab (Keytruda).

20 Feb 2020

Researchers identify a protein that aids in colorectal cancer metastasis

A protein that helps colorectal cancer cells spread to other parts of the body could be an effective treatment target.

20 Feb 2020

Scientists discover novel molecular pathway involved in immunotherapy response

Scientists at The Wistar Institute discovered a novel pathway that enables detection of DNA in the cytoplasm and triggers inflammation and cellular senescence.

20 Feb 2020

Researchers engineer probiotics to safely deliver immunotherapies to tumors

Researchers at Columbia Engineering have engineered probiotics to safely deliver immunotherapies within tumors.

12 Feb 2020

Avacta demonstrates initial proof-of-concept for TMAC drug conjugates in pre-clinical study

Avacta Group plc, the developer of Affimer biotherapeutics and reagents, is pleased to announce that it has demonstrated initial proof-of-concept for its proprietary new class of drug conjugate, TMAC, in a pre-clinical animal model of cancer.

From Avacta Life Sciences Ltd. 28 Jan 2020

Community-based program enables donation of tumor tissue and blood samples for research

Precision medicine with targeted therapies has led to improved treatment options and patient outcomes. These approaches were developed by studying tumors grown in laboratories and patient samples obtained before and during their treatment.

14 Dec 2019

Stem cell transplant following treatment with PD-1 inhibitor is safe, effective for patients with Hodgkin lymphoma

A new analysis shows that a donor stem cell transplant following treatment with an immune checkpoint inhibitor is generally safe and produces good outcomes for patients with Hodgkin lymphoma, easing concerns that these patients are at heightened risk for severe immune-related complications.

9 Dec 2019

New screening method can rapidly discover potential cancer-treating compounds

Scientists at Scripps Research have developed a method for rapidly discovering potential cancer-treating compounds that work by resurrecting anti-tumor activity in immune cells called T cells.

3 Dec 2019

Study: TBK1 protein promotes cancer development, suppresses immune response to the disease

Researchers at The University of Texas MD Anderson Cancer Center have found that a protein involved in immune response to microbes also can fuel cancer development and suppress immune response to the disease.

3 Dec 2019

Study suggests two new approaches against bone metastases from prostate cancer

When prostate cancer spreads, it most often spreads to bone. And while the 5-year survival rate for prostate cancer that has not spread is nearly 100 percent, once the disease reaches bone, the 5-year survival rate is only 29 percent.

2 Dec 2019

Prostate cancer 'super responders' could live for two years or more on immunotherapy

Some men with advanced prostate cancer who have exhausted all other treatment options could live for two years or more on immunotherapy, a major clinical trial has shown.

27 Nov 2019

Combination therapy improves survival in patients with hepatocellular carcinoma

Combination therapy with the PD-L1 inhibitor atezolizumab and the VEGF inhibitor bevacizumab significantly improves overall survival and progression-free survival in patients with unresectable hepatocellular carcinoma compared to standard of care, showed results from a phase 3 study reported at the ESMO Asia 2019 Congress.

22 Nov 2019

Promising method to identify aggressive breast cancers that will respond to immunotherapy

University of North Carolina Lineberger Comprehensive Cancer Center researchers have discovered a promising method to identify aggressive breast cancer tumors that will respond to drugs that unleash the immune system against cancer.

14 Nov 2019

NCCN ORP plans to support phase II randomized trial for lung cancer patients

The National Comprehensive Cancer Network Oncology Research Program today announced plans to support a phase II randomized trial for lung cancer patients.

28 Oct 2019

Oncolytics Biotech and PrECOG collaborate to study metastatic breast cancer

Oncolytics Biotech Inc. , currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, and PrECOG LLC, a leading cancer research network, today announced their collaboration in which PrECOG will run the BRACELET-1 (PrE0113) study.

22 Oct 2019

Creatine serves as a molecular battery to power killer T cells' fight against cancer

Creatine, the organic acid that is popularly taken as a supplement by athletes and bodybuilders, serves as a molecular battery for immune cells by storing and distributing energy to power their fight against cancer, according to new UCLA research.

18 Oct 2019

Study: High levels of circ E7 is a positive prognostic marker in anal squamous cell carcinoma

High levels of circ E7 by quantitative RT-PCR predicted improved overall survival in ASCC and analysis of The Cancer Genome Atlas sequencing from HPV-positive head and neck cancer and cervical cancer suggested high circ E7 marked improved survival in 875 subjects.

17 Oct 2019

PD L1 News and Research

Global study shows long-term survival benefit for a subset of patients with advanced lung cancer

Researchers identify a protein that aids in colorectal cancer metastasis

Scientists discover novel molecular pathway involved in immunotherapy response

Researchers engineer probiotics to safely deliver immunotherapies to tumors

Avacta demonstrates initial proof-of-concept for TMAC drug conjugates in pre-clinical study

Community-based program enables donation of tumor tissue and blood samples for research

Stem cell transplant following treatment with PD-1 inhibitor is safe, effective for patients with Hodgkin lymphoma

New screening method can rapidly discover potential cancer-treating compounds

Study: TBK1 protein promotes cancer development, suppresses immune response to the disease

Study suggests two new approaches against bone metastases from prostate cancer

Prostate cancer 'super responders' could live for two years or more on immunotherapy

Combination therapy improves survival in patients with hepatocellular carcinoma

Promising method to identify aggressive breast cancers that will respond to immunotherapy

NCCN ORP plans to support phase II randomized trial for lung cancer patients

Oncolytics Biotech and PrECOG collaborate to study metastatic breast cancer

Creatine serves as a molecular battery to power killer T cells' fight against cancer

Study: High levels of circ E7 is a positive prognostic marker in anal squamous cell carcinoma

New protein painting technology could transform drug discovery process

Novel immunotherapy combination could provide fresh hope for patients with cervical cancer

Higher levels of genetic mutations linked to improved outcomes in lung cancer patients

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News